Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958483 | 1.00 | FPR2 (0.65) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL25332329 | 0.98 | FPR2 (0.62) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL18398852 | 0.92 | FPR2 (0.56) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL18398851 | 0.92 | FPR2 (0.56) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL4566258 | 0.86 | FPR2 (0.48) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL28080055 | 0.86 | FPR2 (0.48) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL1015737 | 0.85 | FPR2 (0.56) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL1015738 | 0.85 | FPR2 (0.56) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL9478232 | 0.85 | ACHE (0.69) | FPR2NFKB1NFKB2RELAACHE | |
| SCHEMBL31323256 | 0.85 | ACHE (0.69) | FPR2NFKB1NFKB2RELAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173285-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-30 | — | — | US | claimed |
| EP-4329742-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-03-06 | — | — | EP | claimed |
| CN-115698252-A | Dairy product composition | 生物乳业公司 | 2023-02-03 | — | — | CN | claimed |
| EP-3502703-A1 | METHOD FOR THE ASSESSMENT OF NAFLD | Metanomics Health GmbH (DE) | 2019-06-26 | — | — | EP | claimed |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250281926-A1 | SAMPLE MANIPULATION AND ASSAY WITH RAPID TEMPERATURE CHANGE | ESSENLIX CORPORATION (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250262276-A1 | METHODS OF INHIBITING BOVINE MASTITIS DURING THE DRY PERIOD | ELANCO US INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250099965-A1 | RAPID SAMPLE TEMPERATURE CHANGING FOR ASSAYING | ESSENLIX CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226769-B2 | Sample manipulation and assay with rapid temperature change | ESSENLIX CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12064771-B2 | Rapid sample temperature changing for assaying | ESSENLIX CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240173285-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-30 | — | — | US | disclosed |
| EP-2607902-A1 | Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof | Lipomics Technologies, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2507633-A1 | MEANS AND METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS | Metanomics Health GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-20120238028-A1 | Means and Methods for Diagnosing Multiple Sclerosis | METANOMICS HEALTH GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2011067243-A1 | MEANS AND METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS | METANOMICS HEALTH GMBH (DE) | 2011-06-09 | — | — | WO | disclosed |
| US-20100233724-A1 | MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF | METABOLON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-6534282-B2 | Measurement concentration of hydroxyeicostrienoic acid | DETROIT R&D, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6440682-B1 | ASSESSING HYPERTENSION BY MEASURING THE AMOUNT OF FREE AND CONJUGATED HYDROXYEICOSATRIENOIC ACIDS (DHETS) AND METABOLITES OF DHETS, WHICH ARE METABOLITES OF ARACHIDONIC ACID EPOXYGENASES AND EPOXIDE HYDROLASES | DETROIT R&D INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020025544-A1 | Detection of hypertension using immunoreactive metabolic products | DETROIT R&D, INC. | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | ALOX5, ALOX15, ALOX15B | FPR2 285/4885NFKB1 702/4885NFKB2 1407/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | FPR2 869/4885NFKB1 1522/4885NFKB2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.